Abacavir Sulfate is a nucleoside reverse transcriptase inhibitor (NRTI) that, once intracellularly phosphorylated, terminates HIV-1 reverse transcription by competing with the natural nucleotide substrate. Its use requires HLA-B*5701 genetic screening due to a well-documented hypersensitivity risk, making rigorous quality control of the API itself equally critical. Simson Pharma's Abacavir Sulfate reference standard and impurity panel support antiretroviral generic development and compendial testing.
Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Abacavir Sulfate Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.